Project Grant R35HL184269
Award Date 4/1/26
Completion Date 1/31/33
Dollars Obligated $1.2M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10029, USA
Similar Awards
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Columbia University's Health Sciences Division a $1,394,592 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) on August 5, 2025, with completion targeted for March 31, 2026. This research initiative investigates epitranscriptomic regulation of hematopoietic stem cell (HSC) niche generation and regeneration, focusing on the role of N6-methyladenosine (M6A) mRNA modifications in...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $776,511 Project Grant to Fred Hutchinson Cancer Center (Seattle, WA) effective September 1, 2025, through May 31, 2029, under the Cardiovascular Diseases Research program (CFDA 93.837). This award funds research to develop and validate a three-dimensional (3D) engineered hemogenic vascular niche model that replicates the microenvironmental conditions necessary for hematopoietic stem cell (HSC) genesis...
- Federal Grant Award Summary Albert Einstein College of Medicine received a $271,562 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective July 9, 2025, with a completion date of March 31, 2028. The award funds research to elucidate the interplay between DDX41 (DEAD-box helicase 41) and CUX1 (cut-like homeobox 1) mutations in hematopoiesis, addressing the incompletely understood pathogenesis of...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant of $166,644 to The Trustees of Columbia University in the City of New York (Health Sciences Division) on July 16, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837). The award supports research investigating inflammatory responses in human hematopoietic stem cells (HSCs) with a focus on understanding how aging and clonal hematopoiesis—specifically TET2 mutations—alter...
- Federal Grant Award Summary Boston Medical Center Corporation received a $1.42 million Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective May 1, 2025, through February 28, 2030. The award supports research to elucidate the endothelial mechanisms that regulate hematopoietic stem cell (HSC) extravasation—the process by which circulating stem cells cross blood vessel walls and enter their bone marrow...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Icahn School of Medicine at Mount Sinai a Project Grant of $843,607 on June 4, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to support research on the immune-mediated heart-brain axis and its relationship to sleep following ischemic cardiac injury. The project, scheduled for completion by April 30, 2029, will investigate neuroimmune pathways regulating sleep after...
- Federal Grant Award Summary The Icahn School of Medicine at Mount Sinai (ISMMS) received a $447,977 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) for the period September 1, 2025, through August 31, 2030. The award supports the Cardiovascular Science Training Program (CSTP), a research training initiative designed to recruit and develop pre-doctoral and post-doctoral scientists pursuing independent...
- Federal Project Grant Award Summary New York University School of Medicine received a $1,504,727 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective May 1, 2025, through February 28, 2029. The award funds research to define targetable vulnerabilities in UBA1-mutated hematopoietic stem cells (HSCs) associated with VEXAS (Vacuoles E1 enzyme X-linked Autoinflammatory Somatic) syndrome, with the...
- Federal Grant Award Summary Icahn School of Medicine at Mount Sinai received a $713,421 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 3, 2025, with completion targeted for June 30, 2029. The grant funds research to elucidate the physiological mechanisms linking thin filament architecture regulation to myopathies, particularly dilated cardiomyopathy (DCM) and nemaline myopathy. The...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Icahn School of Medicine at Mount Sinai a $730,268 Project Grant on August 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a versatile paired prime editing toolkit for cystic fibrosis transmembrane conductance regulator (CFTR) gene correction. The award supports a research project with a completion date of May 31, 2030, focused on creating a generalizable genome...